ELDN实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 04:00):

Stats
今日成交量	146 819
平均成交量	95 681.00
市值	55.41M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.400
ATR14	$0.0160 (0.70%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-02	Robinson James A. Jr.	Buy	150 437	Stock Option (Right to Buy)
2023-10-02	Kirk Allan	Buy	150 437	Stock Option (Right to Buy)
2023-10-01	Robinson James A. Jr.	Buy	0
2023-10-02	Kirk Allan	Buy	0
2023-05-05	Bvf Partners L P/il	Buy	3 084 090	Warrants to Purchase Common Stock

INSIDER POWER
100.00
Last 95 transactions
Buy: 17 704 764 \| Sell: 1 858 032

音量相关性

長: 0.10 (neutral)

短: 0.51 (weak)

Signal:(51.425) Neutral

Eledon Pharmaceuticals, 相关性

10 最正相关
GLPG	0.883
HAIN	0.848
NSTG	0.845
ONEM	0.844
RMRM	0.842
CLLS	0.841
FREQ	0.833
SOPA	0.832
MLAB	0.825
AIHS	0.825

10 最负相关
ACLS	-0.87
RDI	-0.865
INOD	-0.859
DMAC	-0.851
SPSC	-0.849
IESC	-0.846
CTLP	-0.845
NVTS	-0.844
VRRM	-0.84
ALOR	-0.84

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Eledon Pharmaceuticals, 相关性 - 货币/商品

-0.45
( neutral )

-0.63
( weak negative )

0.00
( neutral )

-0.50
( neutral )

0.47
( neutral )

Eledon Pharmaceuticals, 财务报表

Annual	2023
营收:	$0
毛利润:	$-374 000 (0.00 %)
EPS:	$-1.640

FY	2023
营收:	$0
毛利润:	$-374 000 (0.00 %)
EPS:	$-1.640

FY	2022
营收:	$0
毛利润:	$-373 000 (0.00 %)
EPS:	$-6.13

FY	2021
营收:	$120 000
毛利润:	$120 000 (100.00 %)
EPS:	$-17.31

Financial Reports:

No articles found.

Eledon Pharmaceuticals,

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.